Back to browse

EXP001661

Paper

Nose-to-brain delivery of enveloped RNA - cell permeating peptide nanocomplexes for the treatment of neurodegenerative diseases (2020)

Peptide

C12-r8 (lauric acid–octaarginine)

Sequence: C12-r8 (D-type octaarginine; lauric acid coupled to N-terminus of D-octaarginine)

RNA

miRNA

All experiment fields

Experiment Id EXP001661
Paper Nose-to-brain delivery of enveloped RNA - cell permeating peptide nanocomplexes for the treatment of
Peptide C12-r8 (lauric acid–octaarginine)
Delivery Success Class no
In Vivo Flag no
Uptake Confirmed yes
Label Confidence medium
In Vitro Functional Effect
Endosomal Escape Evidence
Peptide Concentration
Rna Concentration 400 nM miR-132 mimic (final, in Opti-MEM; 4 h)
Mixing Ratio N/P (C12-r8:RNA) = 4:1; polymer envelopment stepwise
Formulation Format Enveloped nanocomplex (ENCP): core C12-r8/miRNA nanocomplex electrostatic, shell PEG-PGA
Formulation Components C12-r8 complexed with miR-132 mimic at N/P 4:1 (core NCP), then enveloped with PEG-PGA (50 µL of 1 mg/mL per 1 mL NCP) | Enveloping polymer: PEG-PGA (mPEG45.5k-b-PGA10; 22 kDa total)
Size Nm 96.00
Zeta Mv 4.00
Model Scope in_vitro
Model Type in vitro
Cell Lines Or Primary Cells CHO cells (4 h incubation)
Animal Model
Administration Route
Output Type Cellular uptake/internalization (qPCR of miR-132 levels after incubation)
Output Value ~14,000-fold increase vs endogenous miR-132 (higher than RNAiMAX)
Output Units
Output Notes qPCR quantification after washing/trypsinization; compared vs RNAiMAX and HA ENCPs.
Toxicity Notes
Curation Notes